Withdrawal of biologic therapy in juvenile idiopathic arthritis due to remission: predictors of flare and outcomes

References

• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Horton DB, Onel KB, Beukelman T, et al. Approaches for Withdrawing drugs for children with clinically inactive nonsystemic JIa: a survey of the childhood arthritis and rheumatology research alliance. J Rheumatol. 2017;44(3):352–360.
   PubMed Web of Science ®Google Scholar
• Horton DB, Salas J, Wec A, et al. Making decisions about stopping medicines for well-controlled juvenile idiopathic arthritis: a mixed-methods study of patients and caregivers. Arthritis Care Res (Hoboken). 2021;73(3):374–385.
   PubMed Web of Science ®Google Scholar
• Sozeri B, Emine Sonmez H, Demir F, et al. Time to collaborate: objectives, design, and methodology of PeRA-Research Group. North Clin Istanb. 2021;8(2):200–202.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290–2294.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–666.
   PubMed Web of Science ®Google Scholar
• Ter Haar NM, Ehp VD, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019;71(7):1163–1173.
   PubMed Web of Science ®Google Scholar
• Guzman J, Oen K, Huber AM, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the reacch-out cohort. Ann Rheum Dis. 2016;75(6):1092–1098.
   PubMed Web of Science ®Google Scholar
• Alexeeva E, Horneff G, Dvoryakovskaya T, et al. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial. Pediatr Rheumatol Online J. 2021;19(1):5.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–2021.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77(12):1710–1719.
   PubMed Web of Science ®Google Scholar
• Simonini G, Ferrara G, Pontikaki I, et al. Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration. Arthritis Care Res (Hoboken). 2018;70(7):1046–1051.
   PubMed Web of Science ®Google Scholar
• Pediatric Rheumatology International Trials O, CA W, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31(11):2290–2294.
   PubMed Web of Science ®Google Scholar
• Minden K, Horneff G, Niewerth M, et al. Time of disease-modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood. Arthritis Care Res (Hoboken). 2019;71(4):471–481.
   PubMed Web of Science ®Google Scholar
• Aquilani A, Marafon DP, Marasco E, et al. Predictors of flare following etanercept withdrawal in patients with rheumatoid factor-negative juvenile idiopathic arthritis who reached remission while taking medication. J Rheumatol. 2018;45(7):956–961.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Johnson AL, Huang B, et al. Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease. Arthritis Rheumatol. 2018;70(9):1508–1518.
   PubMed Web of Science ®Google Scholar
• Su Y, Yang YH, Chiang BL. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes. Clin Rheumatol. 2017;36(9):1997–2004.
   PubMed Web of Science ®Google Scholar
• Remesal A, Dei J, Merino R, et al. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol. 2010;37(9):1970–1971.
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(7):1228–1229.
   PubMed Web of Science ®Google Scholar
• Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78(1):51–59.
   PubMed Web of Science ®Google Scholar
• Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015;67(5):658–666.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41(12):2459–2465.
   PubMed Web of Science ®Google Scholar
• Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74(4):553–569.
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133–1138.
   PubMed Web of Science ®Google Scholar
• Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965–971.
   PubMed Web of Science ®Google Scholar
• Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–426.
   PubMed Web of Science ®Google Scholar
• Ter Haar NM, Tak T, Mokry M, et al. Reversal of sepsis-like features of neutrophils by interleukin-1 blockade in patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(6):943–956.
   PubMed Web of Science ®Google Scholar
• Baszis K, Garbutt J, Toib D, Mao J, King A, White A, et al. Clinical outcomes after withdrawal of anti-tumor necrosis factor alpha therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum. 2011;63(10):3163–3168.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405–1413.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63(2):545–555.
   Google Scholar
• Klotsche J, Minden K, Niewerth M, et al. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Ann Rheum Dis. 2018;77(7):996–1002.
   PubMed Web of Science ®Google Scholar
• Martini A, Ravelli A, Avcin T, et al. toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–197.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52(3):826–832.
   PubMed Web of Science ®Google Scholar
• Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71(9):1437–1439.
   PubMed Web of Science ®Google Scholar
• Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol. 2003;30(9):1900–1903.
   PubMed Web of Science ®Google Scholar
• Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303(13):1266–1273.
   PubMed Web of Science ®Google Scholar
• Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69(9):1636–1642.
   PubMed Web of Science ®Google Scholar
• Ringold S, Dennos AC, Kimura Y, et al. Disease recapture rates after medication discontinuation and flare in JIA: an observational study within the childhood arthritis and rheumatology research alliance registry. arthritis care res (Hoboken). 2022.
   Google Scholar